Consequently, SGLT2 inhibitors may regulate SIRT1 activity, modulate autophagy flux, and reduce ROS levels, thereby influencing atrial fibrosis and AF through both direct and indirect mechanisms. This evidence concerns the gene SLC5A2 and atrial fibrillation.